Year: 2020
Type: article
Abstract: vs cisplatin alone.Analysis was stratified to 1 of 3 cohorts: germline BRCA variant, BRCA-like, or non-BRCA.The BRCA variant and BRCA-like groups that received combined therapy showed a statistically significant improvement in PFS and improved overall survival, although the difference for overall survival was not significant.6 The Hallmarks of Cancer paradigm advances the perspective that understanding the disruption of genomic pathways or circuits is more important than single gene variations.7 Comprehensive sequencing of human cancers is confirming that view and revealing that seemingly disparate malignant neoplasms may be more similar than not, as exemplified by the many cancers that share HRR pathway disruptions.Clinical trials guided by molecular signatures will refine the prediction of response or resistance in cohorts and individuals.The blurred distinction between clinical research and standards of practice will create new challenges and opportunities to translate research into practice (ie, implementation science) and to improve systems of care that ensure routine adherence to these new standards (ie, improvement science).
Source: JAMA Network Open
Authors: Mili Arora, Frederick J. Meyers
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,000
OpenAlex ID: W3097846513